AMGN vs CBRE · P/E 24, rev $10.05B vs P/E 43, rev $21.75B
Amgen Inc (AMGN) versus CBRE Group Inc Class A (CBRE) — a side-by-side from cached financials, not a winner call.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
CBRE Group Inc Class A (CBRE) is a real estate services company listed on US.
Latest reported AMGN revenue for 2026-06-30 was $10.05B. Net income was $2.38B. Revenue was up 16.7% from 2026-03-31 to 2026-06-30. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
Latest reported CBRE revenue for 2026-06-30 was $21.75B. Net income was $522.0M. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
AMGN currently screens at market cap $188.67B and trailing P/E 24.3. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
Not investment advice. Open the AMGN and CBRE stock pages for the full models.
Not investment advice.